Pacira(US:PCRX) Globenewswire·2026-02-26 21:01Core Insights - Pacira BioSciences reported record-high sales of EXPAREL, driven by a 7% volume growth, marking the strongest fourth-quarter performance in three years [1][4] - The company generated $726 million in total revenue for 2025, a 4% increase from $701 million in 2024, with EXPAREL net product sales reaching $575.1 million, up 5% from $549 million in the previous year [9][11] Financial Highlights - Fourth quarter revenues were $196.9 million, a 5% increase from $187.3 million in Q4 2024 [9][12] - GAAP net income for Q4 2025 was $1.6 million, or $0.04 per share, compared to $16 million, or $0.35 per share, in Q4 2024 [9][12] - Full-year GAAP net income was $7 million, or $0.16 per share, compared to a net loss of $99.6 million in 2024 [11][12] - Adjusted EBITDA for Q4 2025 was $38.7 million, down from $62.5 million in Q4 2024, while full-year adjusted EBITDA was $186.5 million, compared to $223.9 million in 2024 [9][19] Business Developments - The company appointed Samit Hirawat, M.D., to its Board of Directors, enhancing its leadership with over 25 years of clinical development experience [9][14] - A strategic partnership with LG Chem was established to expand the commercialization of EXPAREL in select Asia-Pacific markets, with LG Chem receiving exclusive rights to market the product in the region [9][14] Product Performance - EXPAREL sales in Q4 2025 were $155.8 million, a 5% increase from $147.7 million in Q4 2024 [9][12] - ZILRETTA net product sales were $33 million in Q4 2025, essentially flat compared to $33.1 million in Q4 2024, while iovera° sales increased by 8% to $7 million [11][12] - Total operating expenses for Q4 2025 were $194.5 million, up from $162.5 million in Q4 2024, driven by increased R&D and SG&A expenses [12][19] Future Guidance - For 2026, the company provided guidance of $600 to $620 million in EXPAREL net product sales and total revenue of $745 million to $770 million [20]